PUBLIC LAW 107-172—MAY 14, 2002 116 STAT. 541 Public Law 107-172 107th Congress An Act To amend the Public Health Service Act to provide for research, information, and education with respect to blood cancer. Be it enacted by the Senate and House of Representatives of the United States of America in Congress assembled, SECTION 1. SHORT TITLE. This Act may be cited as the "Hematological Cancer Research Investment and Education Act of 2002". SEC. 2. FINDINGS. Congress finds that: (1) An estimated 109,500 people in the United States will be diagnosed with leukemia, lymphoma, and multiple myeloma in 2001. (2) New cases of the blood cancers described in paragraph (1) account for 8.6 percent of new cancer cases. (3) Those devastating blood cancers will cause the deaths of an estimated 60,300 persons in the United States in 2001. Every 9 minutes, a person in the United States dies from leukemia, l5rmphoma, or multiple myeloma. (4) While less than 5 percent of Federal funds for cancer research are spent on those blood cancers, those blood cancers cause 11 percent of all cancer deaths in the United States. (5) Increased Federal support of research into leukemia, lymphoma, and multiple myeloma has resulted and will continue to result in significant advances in the treatment, and ultimately the cure, of those blood cancers as well as other cancers. SEC. 3. RESEARCH, INFORMATION, AND EDUCATION WITH RESPECT TO BLOOD CANCER. Part C of title IV of the Public Health Service Act (42 U.S.C. 285 et seq.) is amended by inserting after section 419C the following: ••SEC. 417D. RESEARCH, INFORMATION, AND EDUCATION WITH RE- SPECT TO BLOOD CANCER. "(a) JOE MOAKLEY RESEARCH EXCELLENCE PROGRAM.— "(1) IN GENERAL. —The Director of NIH shall expand, intensify, and coordinate programs for the conduct and support of research with respect to blood cancer, and particularly with respect to leukemia, Ijnnphoma, and multiple myelom.a. "(2) ADMINISTRATION. —The Director of NIH shall carry out this subsection through the Director of the National Cancer Institute and in collaboration with any other agencies that the Director determines to be appropriate. May 14, 2002 [S. 1094] Hematological Cancer Research Investment and Education Act of 2002. 42 USC 201 note. 42 USC 285a-10 note 42 USC 285a-10.
�
